MedPath
FDA Approval

TRUSELTIQ

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
QED Therapeutics, Inc.
DUNS: 081223065
Effective Date
February 7, 2022
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Infigratinib(50 mg in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Helsinn Healthcare SA

481466936

Products4

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

TRUSELTIQ

Product Details

NDC Product Code
72730-506
Application Number
NDA214622
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
June 3, 2021
Code: A4055ME1VKClass: ACTIMQuantity: 50 mg in 1 1

TRUSELTIQ

Product Details

NDC Product Code
72730-101
Application Number
NDA214622
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
June 3, 2021
Code: A4055ME1VKClass: ACTIMQuantity: 125 mg in 1 1

TRUSELTIQ

Product Details

NDC Product Code
72730-202
Application Number
NDA214622
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
June 3, 2021
Code: A4055ME1VKClass: ACTIMQuantity: 75 mg in 1 1

TRUSELTIQ

Product Details

NDC Product Code
72730-111
Application Number
NDA214622
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
June 3, 2021
Code: A4055ME1VKClass: ACTIMQuantity: 100 mg in 1 1
© Copyright 2025. All Rights Reserved by MedPath